EXHIBIT 10.4(a) CONSULTING AGREEMENT This Consulting Agreement (the "Agreement") is entered into effective as of December 28, 2001, by and between AspenBio, Inc., a Colorado corporation (the "Company") and Cambridge Holdings, Ltd., a Colorado...Consulting Agreement • April 12th, 2002 • Aspenbio Inc • Colorado
ARTICLE I THE LOAN --------Loan Agreement • March 26th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
ARTICLE 1 TERM OF EMPLOYMENT ------------------Executive Employment Agreement • August 30th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
EXHIBIT 10.26 ------------- This Note has not been registered under the Securities Act of 1933, as amended (the "Act'), and is a "restricted security," as that term is defined in Rule 144 under the Act. This Note may not be offered for sale, sold, or...Promissory Note • June 24th, 2003 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
UNDERWRITING AGREEMENT between ASPENBIO PHARMA, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters ASPENBIO PHARMA, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • June 20th, 2012 • AspenBio Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
The undersigned, AspenBio Pharma, Inc., a corporation formed under the laws of the State of Colorado (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of AspenBio Pharma, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
Venaxis, Inc. 8,335,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • April 3rd, 2014 • Venaxis, Inc. • In vitro & in vivo diagnostic substances • New York
Venaxis, Inc., a Colorado corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 8,335,000 shares (the “Underwritten Shares”) of common stock, no par value per share, of the Company (the “Common Stock”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional 1,250,250 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
ASPENBIO, INC.Stock Option Agreement • April 12th, 2002 • Aspenbio Inc
EXHIBIT 10.18(b) PLEDGE AGREEMENT PLEDGE AGREEMENT (the "AGREEMENT"), dated as of the 5th day of July, 2002 between AspenBio, Inc., a Colorado corporation ("PLEDGOR"), and Michael S. Smith ("PLEDGEE"). WHEREAS, Pledgee has loaned to Pledgor $500,000...Pledge Agreement • July 8th, 2002 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
BIOPTIX, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIESIndenture • February 8th, 2017 • Bioptix, Inc. • In vitro & in vivo diagnostic substances • New York
WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securities (hereinafter referred to as the "Securities"), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
EXHIBIT 10.4(b) [AspenBio Letterhead] March __, 2002 Gregory Pusey President Cambridge Holdings, Ltd. 106 S. University Blvd. Unit 14 Denver, CO 80209 Re: Consulting Agreement by and between AspenBio, Inc. (the "Company") and Cambridge Holdings, Ltd....Consulting Agreement • April 12th, 2002 • Aspenbio Inc
EXHIBIT 10.22 ------------- LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (the "Lock-up Agreement") is entered into effective as of June 9, 2003, by and between Roger D. Hurst (the "Shareholder"), a shareholder of AspenBio, Inc., a Colorado corporation...Lock-Up Agreement • June 24th, 2003 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
EXHIBIT 10.6 VOTING AGREEMENT THIS VOTING AGREEMENT (the "Voting Agreement") is entered into effective as of June 18, 2003, by and between Roger D. Hurst ("Hurst"), and AspenBio, Inc., a Colorado corporation (the "Company"). WHEREAS, Hurst owns...Voting Agreement • March 29th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
Riot Platforms, Inc. Shares of Common Stock (no par value per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • August 9th, 2024 • Riot Platforms, Inc. • Finance services
Riot Platforms, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co., B. Riley Securities, Inc., BTIG, LLC, Roth Capital
RECITALSInvestor Rights Agreement • July 8th, 2002 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
RECITALSShareholder Agreement • April 12th, 2002 • Aspenbio Inc • Colorado
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 28th, 2011 • AspenBio Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 23, 2011, between AspenBio Pharma, Inc., a Colorado corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT VENAXIS, inc.Common Stock Purchase Warrant • May 23rd, 2013 • Venaxis, Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Original Issue Date”) and on or prior to 5:30 p.m., New York City time, on the date that is ___ years following the Original Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Venaxis, Inc., a Colorado corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of ______ share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
FORM OF COMMON STOCK PURCHASE WARRANTSecurities Agreement • December 19th, 2017 • Riot Blockchain, Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, [______] or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six month anniversary of the Initial Issuance Date (the "Initial Exercise Date") and on or prior to the close of business on the thirty six (36) month anniversary of the Initial Exercise Date (the "Termination Date") but not thereafter, to subscribe for and purchase from RIOT BLOCKCHAIN, INC., a Nevada corporation (the "Company"), up to [____] shares (as subject to adjustment hereunder, the "Warrant Shares") of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
UNDERWRITING AGREEMENT between ASPENBIO PHARMA, INC. and AEGIS CAPITAL CORP., as Representative of the Several UnderwritersUnderwriting Agreement • November 16th, 2012 • AspenBio Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
The undersigned, AspenBio Pharma, Inc., a corporation formed under the laws of the State of Colorado (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of AspenBio Pharma, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with Aegis Capital Corp. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
AT THE MARKET OFFERING AGREEMENTAt the Market Offering Agreement • May 24th, 2019 • Riot Blockchain, Inc. • In vitro & in vivo diagnostic substances • New York
Riot Blockchain, Inc., a corporation organized under the laws of the State of Nevada (the “Company”), confirms its agreement (this “Agreement”) with H.C Wainwright & Co., LLC (the “Manager”) as follows:
EXHIBIT 10.25 EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 16th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Missouri
EXHIBIT 10.27 ------------- VOTING AGREEMENT THIS VOTING AGREEMENT (the "Voting Agreement") is entered into effective as of June 18, 2003, by and between Roger D. Hurst ("Hurst"), and AspenBio, Inc., a Colorado corporation (the "Company"). WHEREAS,...Voting Agreement • June 24th, 2003 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
for the purchase of Units Each Unit consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock ofCommon Stock and Warrant Purchase Agreement • August 12th, 2005 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
2% CONVERTIBLE NOTE DUE [____], 2018Convertible Security Agreement • March 17th, 2017 • Bioptix, Inc. • In vitro & in vivo diagnostic substances • New York
THIS CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Notes of Bioptix, Inc., a Colorado corporation, (the "Borrower"), having its principal place of business at 1775 38th Street, Boulder CO 80301, due [____], 2018 (this note, the "Note" and, collectively with the other notes of such series, the "Notes").
PLACEMENT AGENCY AGREEMENT December 23, 2011Placement Agency Agreement • December 28th, 2011 • AspenBio Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
ARTICLE 1 TERM OF EMPLOYMENT ------------------Executive Employment Agreement • January 25th, 2005 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
2,409,639 Units ASPENBIO PHARMA, INC. PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • April 30th, 2010 • AspenBio Pharma, Inc. • In vitro & in vivo diagnostic substances • New York
FORM OF COMMON STOCK PURCHASE WARRANTSecurity Agreement • March 17th, 2017 • Bioptix, Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, [______] or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Issuance Date (the "Initial Exercise Date") and on or prior to the close of business on the thirty six (36) month anniversary of the Initial Exercise Date (the "Termination Date") but not thereafter, to subscribe for and purchase from BIOPTIX, INC., a Colorado corporation (the "Company"), up to [____] shares (as subject to adjustment hereunder, the "Warrant Shares") of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
RECITALSTechnology Transfer Agreement • April 12th, 2002 • Aspenbio Inc • Wyoming
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 19th, 2017 • Riot Blockchain, Inc. • In vitro & in vivo diagnostic substances
THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") is made as of _________ 2017, among Riot Blockchain, Inc., a Nevada (the "Company"), the investor signatory hereto (the "Investor"). Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Purchase Agreement (as defined below).
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • November 13th, 2017 • Riot Blockchain, Inc. • In vitro & in vivo diagnostic substances • New York
This SHARE EXCHANGE AGREEMENT (this “Agreement”), dated as of [____], 2017, is by and among Riot Blockchain, Inc., a Nevada corporation (the “Parent”), Kairos Global Technology, Inc., a Nevada corporation (the “Company”), and the shareholders of the Company (each a “Shareholder” and collectively the “Shareholders”). Each of the parties to this Agreement is individually referred to herein as a “Party” and collectively as the “Parties.”
RECITALSDistribution Agreement • April 7th, 2003 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Georgia
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 13th, 2017 • Riot Blockchain, Inc. • In vitro & in vivo diagnostic substances • New York
This EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 3st day of November, 2017 (the “Effective Date”, by and between Riot Blockchain, Inc., a Nevada corporation headquartered at 834-F South Perry Street, Suite 443, Castle Rock, CO 80104 (“Company”) and John O’Rourke, an individual (“Executive”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 17th, 2017 • Bioptix, Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this "Agreement") is dated as of [___], 2017, between Bioptix, Inc., a Colorado corporation (the "Company"), and each purchaser identified on the signature pages hereto (each, including its successors and permitted assigns, a "Purchaser" and collectively, the "Purchasers").
SECURITY AGREEMENTSecurity Agreement • February 1st, 2019 • Riot Blockchain, Inc. • In vitro & in vivo diagnostic substances • Kansas
THIS SECURITY AGREEMENT (this "Agreement"), dated as of January 28, 2019, is by and between RIOT BLOCKCHAIN, INC., a Nevada corporation (the "Grantor"), and [_________] (the “Secured Party”).
